uniQure raises $91.8 million in IPO

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $91.8 million through the sale of a bumped-up number of shares above its proposed price in an IPO. The company sold 5.4 million shares at $17, which values uniQure at $299.1 million. Last month, uniQure said it planned to sell 4.6 million shares at $13-$15. Jefferies; Leerink Partners; and Piper Jaffray are underwriters. uniQure's Glybera alipogene tiparvovec is approved in the EU to treat lipoprotein ( LPL) deficiency in patients with recurring, acute pancreatitis. The company and partner Chiesi Farmaceutici S.p.A. (Parma, Italy) plan to launch Glybera in the EU this half. ...